Affiliation:
1. INSERM U 479, Laboratoire d'Hématologie et Immunologie, CHU Xavier Bichat, 75018 Paris, France
Abstract
ABSTRACT
HMR 3647 (telithromycin), a new ketolide, is active on intracellular pathogens. It was previously demonstrated that it inhibits superoxide anion production in a time- and concentration-dependent manner, at concentrations which inhibit 50% of the control response of about 55 μg/ml (5 min) to 30 μg/ml (30 min); these values are similar to those obtained with roxithromycin, a classical erythromycin A derivative. Here we investigated whether these drugs modified the bactericidal activity of human polymorphonuclear neutrophils (PMN) on four strains of
Staphylococcus aureus
with different profiles of susceptibility to macrolides and ketolides. We found that the main factor involved in killing was the antibacterial potency of the drugs, although combinations of antibiotics with PMN were slightly more active than each component used alone against two of the four strains. In addition, high concentrations of the drugs, which impaired the PMN oxidative burst, did not impair PMN bactericidal activity. Likewise, some cytokines which enhance PMN oxidative metabolism did not modify PMN bactericidal activity in the presence or absence of macrolides or ketolides. These data suggest that oxygen-independent mechanisms contribute to the bactericidal activity of PMN on these strains of
S. aureus
. Both live and/or heat-killed bacteria impaired the uptake of telithromycin and roxithromycin (but not that of levofloxacin, a quinolone) in a concentration-dependent manner, owing to a modulation of PMN transductional systems involved in the activation of the macrolide carrier.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference32 articles.
1. Abdelghaffar, H., D. Vazifeh, and M. T. Labro. 1997. Erythromycin A-derived macrolides modify the functional activities of human neutrophils by altering the phospholipase D-phosphatidate phosphohydrolase transduction pathway. J. Immunol.159:3995-4005.
2. Anderson, R. 1989. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-derived superoxide generation and auto-oxidation. J. Infect. Dis.159:966-973.
3. Anderson, R., A. J. Theron, and C. Feldman. 1996. Membrane-stabilizing anti-inflammatory interactions of macrolides with human neutrophils. Inflammation46:2029-2038.
4. Anderson, R., C.E.J.Van Rensburg, G. Jooné, and P. T. J. Lukey. 1987. An in-vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin. J. Antimicrob. Chemother.20(Suppl. B):57-68.
5. Anderson, R., G. Jooné, and C. E. J. Van Rensburg. 1988. An in-vitro evaluation of the cellular uptake and intraphagocytic activity of clarithromycin (A 56968, TR-031), a new macrolide antimicrobial agent. J. Antimicrob. Chemother.22:923-933.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献